Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

How I treat unexplained refractory iron deficiency anemia.

Hershko C, Camaschella C.

Blood. 2014 Jan 16;123(3):326-33. doi: 10.1182/blood-2013-10-512624. Epub 2013 Nov 8.

2.

Iron, bone, and marrow.

Hershko C.

Blood. 2010 Oct 7;116(14):2405-6. doi: 10.1182/blood-2010-07-293456. No abstract available.

3.

Pathogenesis and management of iron toxicity in thalassemia.

Hershko C.

Ann N Y Acad Sci. 2010 Aug;1202:1-9. doi: 10.1111/j.1749-6632.2010.05544.x.

PMID:
20712765
4.

Iron deficiency, Helicobacter infection and gastritis.

Hershko C, Ronson A.

Acta Haematol. 2009;122(2-3):97-102. doi: 10.1159/000243793. Epub 2009 Nov 10.

PMID:
19907146
5.

Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis.

Hershko C, Skikne B.

Semin Hematol. 2009 Oct;46(4):339-50. doi: 10.1053/j.seminhematol.2009.06.002. Review.

PMID:
19786202
6.

Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.

Taher A, Hershko C, Cappellini MD.

Br J Haematol. 2009 Dec;147(5):634-40. doi: 10.1111/j.1365-2141.2009.07848.x. Epub 2009 Aug 13. Review.

PMID:
19681884
7.

Iron overload in Asia.

Hershko C.

Blood. 2009 Jul 2;114(1):1-2. doi: 10.1182/blood-2009-04-216101.

8.

Ironing out the mechanism of anemia in celiac disease.

Hershko C, Patz J.

Haematologica. 2008 Dec;93(12):1761-5. doi: 10.3324/haematol.2008.000828. Review. No abstract available.

9.

High nontransferrin bound iron levels and heart disease in thalassemia major.

Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini MD.

Am J Hematol. 2009 Jan;84(1):29-33. doi: 10.1002/ajh.21317.

10.

[Conclusions and recommendations of a WHO expert consultation meeting on iron supplementation for infants and young children in malaria endemic areas].

Allen L, Black RE, Brandes N, Brittenham G, Chazot G, Chunming C, Crawley J, de Benoist B, Dalmiya N, Darnton-Hill I, Dewey K, El-Arifeen S, Fontaine O, Geissler C, Haberle H, Harvey P, Hasler J, Hershko C, Hurrell R, Juma MA, Lönnerdal B, Lozoff B, Lynch S, Martines Salgado H, McLean E, Metz J, Oppenheimer S, Premji Z, Prentice A, Ramsan M, Ratledge C, Stoltzfus R, Tielsch J, Winachagoon P; Secrétariat de l'Organisation mondiale de la Santé, au nom des participants à la consultation.

Med Trop (Mars). 2008 Apr;68(2):182-8. French.

11.

Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.

Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E, Hershko C; MDS Israel Group; Israel Society of Hematology.

Isr Med Assoc J. 2008 May;10(5):374-6. No abstract available.

12.

Objectives and methods of iron chelation therapy.

Hershko C, Abrahamov A, Konijn AM, Breuer W, Cabantchik IZ, Pootrakul P, Link G.

Bioinorg Chem Appl. 2003:151-68. doi: 10.1155/S1565363303000128.

13.

Mechanism of iron toxicity.

Hershko C.

Food Nutr Bull. 2007 Dec;28(4 Suppl):S500-9. Review.

PMID:
18297888
14.

Iron loading and its clinical implications.

Hershko C.

Am J Hematol. 2007 Dec;82(12 Suppl):1147-8.

15.

The anemia of achylia gastrica revisited.

Hershko C, Patz J, Ronson A.

Blood Cells Mol Dis. 2007 Sep-Oct;39(2):178-83. Epub 2007 May 9. Review.

PMID:
17493846
17.

A hematologist's view of unexplained iron deficiency anemia in males: impact of Helicobacter pylori eradication.

Hershko C, Ianculovich M, Souroujon M.

Blood Cells Mol Dis. 2007 Jan-Feb;38(1):45-53. Epub 2006 Oct 24.

PMID:
17067833
18.

Oral iron chelators: new opportunities and new dilemmas.

Hershko C.

Haematologica. 2006 Oct;91(10):1307-12. No abstract available.

19.

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI.

Blood. 2006 Nov 1;108(9):3195-203. Epub 2006 Jul 11.

20.

Objectives and mechanism of iron chelation therapy.

Hershko C, Link G, Konijn AM, Cabantchik ZI.

Ann N Y Acad Sci. 2005;1054:124-35. Review.

PMID:
16339658
21.

Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion.

Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J.

Blood. 2006 Feb 15;107(4):1673-9. Epub 2005 Oct 20.

22.

Iron overload and chelation.

Hershko C, Link G, Konijn AM, Ioav Cabantchik Z.

Hematology. 2005;10 Suppl 1:171-3. Review.

PMID:
16188664
23.

[Lead poisoning by contaminated flour: an unfinished story].

Hershko C.

Harefuah. 2005 Jul;144(7):458-62, 528. Hebrew.

PMID:
16082893
24.

Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia.

Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, Lahad A.

Haematologica. 2005 May;90(5):585-95.

25.

Treating iron overload: the state of the art.

Hershko C.

Semin Hematol. 2005 Apr;42(2 Suppl 1):S2-4. Review. No abstract available.

PMID:
15846582
26.

Gastropathic sideropenia.

Hershko C, Lahad A, Kereth D.

Best Pract Res Clin Haematol. 2005 Jun;18(2):363-80.

PMID:
15737896
27.

Iron chelation therapy.

Hershko CM, Link GM, Konijn AM, Cabantchik ZI.

Curr Hematol Rep. 2005 Mar;4(2):110-6.

PMID:
15720959
28.

Transient severe eosinophilia precipitating massive venous thrombosis in a patient with hereditary thrombophilia.

Mates M, Nesher G, Roth B, Rosenberg R, Heyd J, Hershko C.

Acta Haematol. 2004;112(4):209-11.

PMID:
15564733
29.

Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.

Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI.

Blood. 2004 Sep 1;104(5):1504-10. Epub 2004 May 20.

30.

Purging iron from the heart.

Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G.

Br J Haematol. 2004 Jun;125(5):545-51. Review.

PMID:
15147368
31.

Transfusion-related leukocytosis in critically ill patients.

Izbicki G, Rudensky B, Na'amad M, Hershko C, Huerta M, Hersch M.

Crit Care Med. 2004 Feb;32(2):439-42.

PMID:
14758161
32.

Non-transferrin-bound serum iron (NTBI) in megaloblastic anemia: effect of vitamin B(12) treatment.

Gafter-Gvili A, Prokocimer M, Breuer W, Cabantchik IZ, Hershko C.

Hematol J. 2004;5(1):32-4.

PMID:
14745427
33.

Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI.

Blood. 2003 Oct 1;102(7):2670-7. Epub 2003 Jun 12.

34.

Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.

Miskin H, Yaniv I, Berant M, Hershko C, Tamary H.

Eur J Haematol. 2003 Jun;70(6):398-403.

PMID:
12756023
35.

Role of deferiprone in chelation therapy for transfusional iron overload.

Hoffbrand AV, Cohen A, Hershko C.

Blood. 2003 Jul 1;102(1):17-24. Epub 2003 Mar 13. Review. No abstract available.

36.

Cardioprotective effect of iron chelators.

Hershko C, Link G, Konijn AM.

Adv Exp Med Biol. 2002;509:77-89. Review. No abstract available.

PMID:
12572990
37.

Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.

Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.

Blood. 2003 May 15;101(10):4172-9. Epub 2003 Jan 2.

38.

Increased non-transferrin-bound serum iron in megaloblastic anaemia.

Gafter-Gvili A, Prokocimer M, Breuer W, Cabantchik IZ, Hershko C.

Acta Haematol. 2002;108(1):53-4. No abstract available.

PMID:
12145469
39.

Role of Iron Chelation Therapy in Thalassemia Major.

Hershko C.

Turk J Haematol. 2002 Jun 5;19(2):121-6. No abstract available.

PMID:
27264752
40.

The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.

Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C.

J Lab Clin Med. 2002 Jan;139(1):50-8.

PMID:
11873245
44.

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.

Blood. 2001 Feb 1;97(3):792-8.

45.

Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.

Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.

Transfus Sci. 2000 Dec;23(3):241-2. No abstract available.

PMID:
11099901
46.

The importance of non-transferrin bound iron in disorders of iron metabolism.

Breuer W, Hershko C, Cabantchik ZI.

Transfus Sci. 2000 Dec;23(3):185-92. Review.

PMID:
11099894
47.

Re-emergence of lead poisoning from contaminated flour in a West Bank Palestinian village.

Richter E, El-Sharif N, Fischbein A, Konijn A, Gorodetsky R, El-Sharif H, Kaul B, Hershko C, Grauer F, Foner H, Al-Baba A, Dweik Z, Lihsounat M.

Int J Occup Environ Health. 2000 Jul-Sep;6(3):183-6.

PMID:
10926721
48.

The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.

Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.

Blood. 2000 May 1;95(9):2975-82.

49.

Regulation of intracellular iron metabolism in human erythroid precursors by internalized extracellular ferritin.

Meyron-Holtz EG, Vaisman B, Cabantchik ZI, Fibach E, Rouault TA, Hershko C, Konijn AM.

Blood. 1999 Nov 1;94(9):3205-11.

Supplemental Content

Loading ...
Support Center